AbbVie to acquire Gilgamesh Pharmaceutical’s experimental depression drug for up to USD 1.2 billion. The company is seeking to access a fast-growing market for copyright-based treatments. https://www.coherentmarketinsights.com/news/abbvie-to-acquire-gilgameshs-experimental-depression-drug-for-up-to-usd-12-billion-1402